OBJECTIVES In this post hoc analysis of the Ticagrelor in coronary artery bypass grafting
(CABG) trial, we aimed to analyse patients treated with CABG receiving either complete …

OBJECTIVES We evaluated the effect of ticagrelor monotherapy on outcomes after multiple
arterial grafting (MAG) or single arterial grafting (SAG) in coronary artery bypass grafting …

Aims The antiplatelet treatment strategy providing optimal balance between thrombotic and
bleeding risks in patients undergoing coronary artery bypass grafting (CABG) is unclear. We …

Rationale Saphenous vein graft disease remains a major limitation of coronary artery
bypass graft surgery (CABG). Up to 20% of vein grafts will occlude within the first year after …

Background Ticagrelor was shown to reduce mortality in patients who underwent coronary
artery bypass grafting (CABG), but its effect on graft patency is unknown. Methods We …

OBJECTIVES The optimal antiplatelet strategy in patients undergoing CABG remains
unclear. This is the first meta-analysis investigating the clinical outcomes associated with …

Background Prior coronary artery bypass graft surgery (CABG) patients undergoing
percutaneous coronary intervention (PCI) are often older and present with multiple …

Coronary artery bypass graft (CABG) surgery improves symptoms and survival in
appropriately selected patients with multivessel coronary artery disease. 1 However, despite …

Background In the present post hoc analysis of the DACAB trial, we evaluated the effects of
ticagrelor with or without aspirin on 1-year vein graft outcomes after coronary artery bypass …

Background Antiplatelet therapy prevents saphenous vein graft (SVG) occlusion and
improves outcomes after coronary artery bypass graft surgery (CABG). However, the optimal …